Wai Yuen Tong Medicine Holdings Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Kit Man Chan
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 3.3yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
Benign Growth For Wai Yuen Tong Medicine Holdings Limited (HKG:897) Underpins Its Share Price
Sep 03
There's No Escaping Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Muted Revenues Despite A 25% Share Price Rise
Feb 27Wai Yuen Tong Medicine Holdings Limited (HKG:897) Stock Catapults 50% Though Its Price And Business Still Lag The Industry
Jan 06Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Low P/S No Reason For Excitement
Nov 19Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too
Jul 26Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding
Mar 11The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business
Dec 28Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Jul 11Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt
Jul 05Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Mar 08Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now
Aug 18Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Mar 17Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares
Jan 22Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Dec 16
CEO
Kit Man Chan
Mr. Kit Man Chan is Chief Executive Officer of Wai Yuen Tong Medicine Holdings Limited from June 2025. He joined the Wai Yuen Tong Medicine Holdings Limited in June 2025. He has over 30 years of experience...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & MD | 24.3yrs | HK$8.72m | no data | |
| Executive Director | 7.6yrs | HK$2.18m | no data | |
| Assistant GM of Purchasing Processing & Executive Director | 4.8yrs | HK$798.00k | no data | |
| Chief Executive Officer | less than a year | no data | no data | |
| Financial Controller | 2.5yrs | no data | no data | |
| Head of Factory Operations | 4.2yrs | no data | no data | |
| Company Secretary | 1.6yrs | no data | no data |
Experienced Management: 897's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & MD | 24.3yrs | HK$8.72m | no data | |
| Executive Director | 7.6yrs | HK$2.18m | no data | |
| Assistant GM of Purchasing Processing & Executive Director | 4.8yrs | HK$798.00k | no data | |
| Independent Non-Executive Director | 10.7yrs | HK$204.00k | no data | |
| Independent Non-Executive Director | 1.9yrs | HK$184.00k | no data | |
| Independent Non-Executive Director | 1.9yrs | HK$164.00k | no data |
Experienced Board: 897's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 23:14 |
| End of Day Share Price | 2025/11/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Wai Yuen Tong Medicine Holdings Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.